May 8, 2018 / 12:38 PM / 17 days ago

BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse

May 8 (Reuters) - Bellerophon Therapeutics Inc:

* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

* BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS

* BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below